CoChat
Sign Up
Cited by 86Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Wessels, Alette M., Lines, Christopher, Stern, Robert A., Kost, James, Voss, Tiffini, Mozley, Lyn Harper, Furtek, Christine, Mukai, Yuki +11 more·2020·Alzheimer's & Dementia
DOI 10.1002/alz.12164
Open this paper in CoChat — free account

Abstract

Introduction: The APECS and AMARANTH trials showed that beta‐secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on secondary and exploratory cognitive measures in both studies is reported. Methods: APECS (verubecestat) and AMARANTH (lanabecestat) were randomized, double‐blind, placebo‐controlled, parallel‐group, 104‐week clinical trials conducted by different sponsors. Measures included the 3‐Domain Composite Cognition Score (CCS‐3D), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Letter/Category Fluency, and Digit Symbol Coding. Results: Verubecestat showed worsening on the CCS‐3D Total Score, Episodic Memory, and Attention/Processing Speed domains. Lanabecestat showed worsening on the RBANS Total Score, Immediate Memory, and Visuospatial/Constructional Indexes. Both BACE inhibitors showed worsening on Digit Symbol Coding and improvements on Letter/Category Fluency. Discussion: In both studies, many measures showed treatment‐associated cognitive worsening, whereas verbal fluency tasks showed improvement.

Integrity signals

Registry

Crossref · 10.1002/alz.12164

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two consecutive multicenter phase 2a trials show that blarcamesine improves cognition dose-dependently in MMSE and ADCS-ADL in subjects with mild-to-moderate Alzheimer's disease.

    “Two consecutive multicenter phase 2a trials, randomized and open-label, show it improves cognition, dose-dependently, in mini-mental status examination (MMSE) and AD Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) in subjects with mild-to-moderate AD [30].”

    From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [30]

The citation lists haven’t been fetched yet

References 22 · Cited by 86

Authors
Wessels, A. M., Lines, C., Stern, R. A., Kost, J., Voss, T., Mozley, L. H., Furtek, C., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., Dupre, N., Randolph, C., Michelson, D., Andersen, S. W., Shering, C., Sims, J. R., & Egan, M. F.
Affiliations
  • Eli Lilly (United States) (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Boston University (US)
  • University of Southern California (US)
  • Cleveland Clinic (US)
  • Banner Alzheimer’s Institute (US)
  • Inserm (FR)
  • Loyola University Medical Center (US)
  • AstraZeneca (United States) (US)
Corresponding author
Egan, Michael F.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2020-10-13
Volume
16
Issue
11
Pages
1483-1492
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.12164
OpenAlex
W3091786886
Cited by
86
References
22
Citations by year
2026: 7 · 2025: 18 · 2024: 17 · 2023: 15 · 2022: 18 · 2021: 11
FWCI
6.92
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
National Institute on Aging (R35AG071476)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
Keywords
BACE inhibitors, Alzheimer's disease
MeSH terms
Aged, Alzheimer Disease, Cognition, Cyclic S-Oxides, Double-Blind Method, Female, Humans, Imidazoles, Male, Spiro Compounds, Thiadiazines, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review